TRUSTED REPORTING  ·  VERIFIED SOURCES  ·  GLOBAL COVERAGE
Home/Science/Why gene therapy remains unaffordable despite technical success
Science

Why gene therapy remains unaffordable despite technical success

The manufacturing bottleneck stems from the economics of bespoke biological production, not scientific difficulty

Umer

Umer

Senior Correspondent

20 November 2026

6 min read

Why gene therapy remains unaffordable despite technical success

Photo: Unsplash / GlobalTimesOnline

The promise of gene therapy has been realised in the laboratory and the clinic, yet the treatments remain financially out of reach for most health systems. The problem is not that the science has failed to deliver. Therapies exist that can correct genetic defects, halt degenerative diseases, and in some cases offer functional cures. The obstacle lies in how these medicines are made.

Gene therapies depend on viral vectors, typically modified viruses that carry corrective genetic material into a patient's cells. These vectors must be grown in living cell cultures, a process that is labour-intensive, time-consuming, and difficult to standardise. Unlike small-molecule drugs, which can be synthesised in bulk through predictable chemical reactions, each batch of viral vector is a biological event, subject to variability and requiring extensive quality control.

The manufacturing process cannot be easily scaled in the way that transformed antibiotics or statins into mass-market medicines. Increasing production means building more bioreactors, hiring more specialists, and repeating the same bespoke steps. The unit economics do not improve meaningfully with volume. A factory that produces ten thousand doses is not vastly more efficient per dose than one that produces ten.

This structural constraint becomes more acute when therapies are tailored to individual patients. Some gene therapies require extracting a patient's own cells, modifying them outside the body, and reinfusing them. Each treatment is effectively a custom manufacturing run, with dedicated facilities, sterile environments, and rigorous testing. The cost of goods alone can run into six figures before any consideration of research amortisation, regulatory compliance, or profit margin.

The result is a price structure that health systems were not designed to accommodate. Treatments priced in the hundreds of thousands or even millions of pounds per patient force payers into uncomfortable territory. Traditional insurance models spread risk across populations and time, but gene therapies often promise one-time cures, concentrating the financial burden into a single event. The actuarial logic that underpins health funding begins to break down.

For rare diseases affecting small patient populations, the arithmetic was always difficult but containable. A therapy that costs a million pounds but treats only a few dozen patients per year represents a manageable budget line, however uncomfortable the optics. Health systems could absorb these costs as outliers, exceptional cases that did not threaten the broader fiscal framework.

That calculus is changing as gene therapies move into more common conditions. Treatments for haemophilia, sickle cell disease, and certain inherited blindnesses have already been approved. Therapies for muscular dystrophy, heart disease, and neurodegenerative conditions are in advanced trials. If even a modest fraction of patients with these diseases become candidates for gene therapy, the aggregate cost could overwhelm national health budgets.

The political consequences are already visible. Health systems in several countries have declined to fund certain approved gene therapies, citing cost-effectiveness thresholds that were established for conventional treatments. Patients who could be cured are instead managed with palliative care or older therapies, not because the medicine does not work, but because the system cannot afford it. The gap between technical capability and financial reality is widening.

Manufacturers argue that the upfront cost of a gene therapy should be compared to the lifetime expense of managing a chronic disease. A single intervention that eliminates the need for decades of medication, hospital visits, and supportive care may represent value in net present terms. This argument has some merit, but it requires health systems to reallocate capital in ways that are politically and administratively challenging. Budgets are annual; cures are permanent.

Some countries have experimented with instalment payment models, spreading the cost of a gene therapy over several years and linking payments to clinical outcomes. These arrangements are complex to administer and carry their own risks. If a patient moves, dies, or loses insurance, the financial model collapses. If the therapy fails to deliver the expected benefit, clawing back payments becomes a legal and ethical quagmire.

The underlying problem remains the production process. Efforts to industrialise viral vector manufacturing have made incremental progress, but no breakthrough has emerged that would reduce costs by an order of magnitude. The biology is inherently more complex than chemical synthesis. Living cells are sensitive to temperature, pH, nutrient levels, and contamination. They do not follow recipes in the way that chemical reactions do.

Some researchers are exploring alternative delivery mechanisms that might be easier to manufacture at scale. Non-viral vectors, such as lipid nanoparticles, have shown promise in certain applications and are cheaper to produce. The technology used in some recent vaccines demonstrated that lipid-based delivery can be scaled rapidly. Whether these methods can be adapted for gene therapy remains an open question, and they come with their own limitations in targeting and efficacy.

Another line of inquiry involves developing off-the-shelf therapies that do not require patient-specific customisation. These would use donor cells or universal vectors that can be manufactured in large batches and stored. The immunological challenges are significant, as the recipient's immune system may reject foreign cells. Immunosuppression is possible but reintroduces the complications and costs that gene therapy was supposed to eliminate.

The economic pressure is also driving consolidation in the industry. Smaller biotech firms that developed therapies lack the capital to build manufacturing capacity at scale. Larger pharmaceutical companies are acquiring these firms, but the integration process is slow and does not necessarily resolve the cost problem. Manufacturing expertise is scarce, and the facilities required are expensive to build and validate.

Regulatory frameworks add another layer of complexity. Gene therapies are subject to stringent oversight because the risks of error are high. A contaminated batch or a vector that integrates into the wrong part of the genome can cause serious harm. The approval process is lengthy and the standards exacting, which is appropriate given the stakes, but it also increases the cost of bringing a therapy to market. Those costs are ultimately passed to payers and patients.

The tension between innovation and access is not new in medicine, but gene therapy sharpens it. The technologies involved represent some of the most sophisticated achievements in biological science, yet their very sophistication makes them expensive to deploy. The question is whether societies are willing to accept that some cures will remain available only to a fortunate few, or whether new models of funding and production can be devised.

Some health economists argue for a more explicit rationing framework, one that acknowledges scarcity and makes transparent decisions about which treatments will be funded. Others advocate for public investment in manufacturing infrastructure, treating gene therapy production as a strategic asset akin to vaccine capacity. Both approaches require political will and public acceptance of uncomfortable trade-offs.

The alternative is a drift toward a two-tier system in which access to advanced therapies depends on private wealth or lottery-like compassionate use programmes. This outcome would represent a failure not of science but of social organisation, a situation in which the ability to cure is decoupled from the willingness to pay for it at scale.

What remains unresolved is whether the manufacturing challenge is fundamentally intractable or merely unsolved. Chemical synthesis was once expensive and artisanal; industrialisation made it cheap and routine. Biological production may follow a similar trajectory, or it may be constrained by irreducible complexity. The answer will determine whether gene therapy becomes a standard tool in medicine or remains a boutique intervention for those who can afford it.

The stakes extend beyond individual patients. If health systems cannot integrate gene therapies into their funding models, the incentive to develop such treatments may weaken. Investors and researchers may redirect effort toward therapies with more favourable economics, even if they are less effective. The result would be a distortion of medical progress, shaped not by what is scientifically possible but by what is financially viable.

The question facing policymakers is not whether gene therapy works, but whether it can be made to work within the constraints of existing health systems. The answer will shape the future of medicine and the social contract around access to care.

This article was produced with AI assistance and reviewed against our editorial standards.

Umer

Umer

Senior Correspondent

Umer reports on technology, markets, and the forces shaping global news.

Open-source software is fragmenting into walled gardensTechnology

Open-source software is fragmenting into walled gardens

The commons that built the internet is splintering. As open-source code becomes critical infrastructure, volunteer labour and corporate adoption no longer sustain collaboration. The result: incompatible, commercially controlled variants that keep the licensing rhetoric but abandon the practice.

DevenDeven·13 November 2026·6 min
Why parliaments are losing power to bureaucracies they cannot sackPolitics

Why parliaments are losing power to bureaucracies they cannot sack

Democracies have transferred enormous decision-making power to unelected regulators, central banks, and administrative agencies that cannot be dismissed by voters or their representatives. This arrangement was meant to depoliticise technical decisions, but it has created a mismatch between democratic legitimacy and actual authority.

JunaidJunaid·10 November 2026·7 min